This is achieved by down-regulating the activation of the PI3K/AKT/mTOR signaling pathway, inhibiting the downstream vascular endothelial growth factor (VEGF) and VEGFR2, and enhancing tumor cell sensitivity to chemotherapeutic agents. The gene discussed is MTOR; the disease is neoplasm.